Αρχική World News No Additional Benefit From Tiragolumab Plus Atezolizumab Over Durvalumab in Locally Advanced,... World News No Additional Benefit From Tiragolumab Plus Atezolizumab Over Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation Από Ogkologos - 24 Αυγούστου, 2026 170 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SKYSCRAPER-03 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR “The power of science”: HPV vaccine proven to dramatically reduce cervical... 3 Νοεμβρίου, 2021 Significantly Longer PFS with First-line Pembrolizumab for MSI-H/dMMR mCRC 3 Δεκεμβρίου, 2020 September 11, 2001 – Strength is Not Always Unyielding 11 Σεπτεμβρίου, 2021 A Vaccine to Treat Non-Hodgkin Lymphoma Advancing in Clinical Trials 7 Μαΐου, 2019 Φόρτωση περισσοτέρων HOT NEWS Mom Fights Second Round Of Breast Cancer — Weeks Later, Her... Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients... EMA Adopts a New Pharmaceutical Form of Selumetinib Bullies Make Fun Of Little Girl Over Cancer Scars, Her Mom...